← Leaderboards
Chrystal Mary Paulos
Medical University Of South Carolina
$6,163,426
Attributed
$7,491,541
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,491,541 · 6
By mechanism
R01$7,080,062 · 5
R21$411,479 · 1
Top collaborators
- Gregory B. Lesinski3 shared
- David M. Neskey2 shared
- Edmund K. Waller2 shared
Most similar at Medical University Of South Carolina
Same institution · by research overlap
- Laura Goetzl$3,692,223
- David M. Neskey$709,377
Others in their field
Top investigators on “Immunity”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$541,067,641
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$470,748,611
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Judith S. Currier · University Of California Los Angeles$334,425,492
Research focus
ImmunityT-LymphocyteResponseCellsMediatingTumorReportingMalignant NeoplasmsInsightMetabolismPathway InteractionsCd4 Positive T LymphocytesPropertyIn VivoMemoryTumor ImmunityCancer ImmunotherapyImmunotherapyCancer PatientPhenotypeImmune ResponseIn VitroT Memory CellCancer Therapy
Grant awards (19)
Neoadjuvant SEMA4D/ICB therapy for melanoma$709,554
R01 · FY2025 · CA · contact PI
Leveraging CD26high Meso-CAR T cells in patients with advanced pancreatic cancer$638,929
R01 · FY2025 · CA
Mechanisms of Durable Antitumor Immunity Mediated by PI3K-targeted T cells$632,039
R01 · FY2025 · CA · contact PI
Mechanisms of Durable Antitumor Immunity Mediated by PI3K-targeted T cells$603,809
R01 · FY2024 · CA · contact PI
Leveraging CD26high Meso-CAR T cells in patients with advanced pancreatic cancer$575,241
R01 · FY2024 · CA
Mechanisms of Durable Antitumor Immunity Mediated by PI3K-targeted T cells$637,418
R01 · FY2023 · CA · contact PI
Defining the role of CD26 in checkpoint blockaded induced tumor immunity$103,533
R21 · FY2021 · DE
Defining the Role of CD26 in Checkpoint Blockaded Induced Tumor Immunity$83,696
R21 · FY2021 · DE · contact PI
Mechanisms of durable antitumor immunity via CD26hiCD4+ T cells$368,628
R01 · FY2020 · CA · contact PI
Defining the role of CD26 in checkpoint blockaded induced tumor immunity$224,250
R21 · FY2020 · DE
Mechanisms of durable antitumor immunity via CD26hiCD4+ T cells$332,709
R01 · FY2019 · CA · contact PI
Mechanisms of durable antitumor immunity via CD26hiCD4+ T cells$342,972
R01 · FY2018 · CA · contact PI
Mechanisms of durable antitumor immunity via CD26hiCD4+ T cells$345,257
R01 · FY2017 · CA · contact PI
Costimulatory mechanisms of antitumor Th17 cell immunity$310,213
R01 · FY2017 · CA · contact PI
Mechanisms of durable antitumor immunity via CD26hiCD4+ T cells$351,747
R01 · FY2016 · CA · contact PI
Costimulatory mechanisms of antitumor Th17 cell immunity$310,213
R01 · FY2016 · CA · contact PI
Costimulatory mechanisms of antitumor Th17 cell immunity$310,213
R01 · FY2015 · CA · contact PI
Costimulatory mechanisms of antitumor Th17 cell immunity$300,907
R01 · FY2014 · CA · contact PI
Costimulatory mechanisms of antitumor Th17 cell immunity$310,213
R01 · FY2013 · CA · contact PI